Dr. Sha Hao: Focusing on Cellular and Gene Therapy – Project Review Mechanisms and Translational Strategies at the Haihe Laboratory of Cell Ecosystem

Dr. Sha Hao: Focusing on Cellular and Gene Therapy – Project Review Mechanisms and Translational Strategies at the Haihe Laboratory of Cell Ecosystem

As the new year begins, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) took place from January 3 to 5 in Tianjin. With the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being,” the event brought together leading experts and scholars in hematology to discuss the latest advances and future directions in the field. The Haihe Laboratory of Cell Ecosystem, a high-level research platform established in Tianjin, plays a pivotal role in advancing hematology.
2025 CASH丨Professor Jun Shi: Advances in Lentiviral Vector Gene Therapy for Thalassemia

2025 CASH丨Professor Jun Shi: Advances in Lentiviral Vector Gene Therapy for Thalassemia

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event gathered leading experts from China and abroad to discuss the latest advancements and future trends in hematology. Professor Jun Shi, Deputy Director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , followed up on his remarkable presentation at last year’s CASH conference with an update on lentiviral vector gene therapy for thalassemia.In this exclusive feature, Hematology Frontier invited Professor Shi to share the promising clinical results achieved by his team and outline their future research plans.
World’s First! Fatal Cases of Orupuche Fever Confirmed

World’s First! Fatal Cases of Orupuche Fever Confirmed

On the 25th, the Brazilian Ministry of Health announced the confirmation of two fatal cases caused by Orupuche fever. The deceased were two women from the inland region of Bahia State, both under the age of 30 and without any other illnesses. These are the first recorded fatalities due to Orupuche fever worldwide.
For Advanced HR+/HER2- Breast Cancer Patients with Progression after CDK4/6i Treatment, Should We Choose Endocrine Therapy or ADC?

For Advanced HR+/HER2- Breast Cancer Patients with Progression after CDK4/6i Treatment, Should We Choose Endocrine Therapy or ADC?

For advanced HR+/HER2- breast cancer patients with progression after CDK4/6i treatment, would you prefer endocrine therapy or ADC (antibody-drug conjugate) treatment? In the "In-depth Debate" session of the 2024 Breast Cancer Summer Forum - Northern Salon, Dr. Xu Liang from Peking University Cancer Hospital and Dr. Nanlin Li from Xijing Hospital of Air Force Medical University expressed their views. Dr. Xu Liang favored endocrine therapy, while Dr. Nanlin Li preferred ADC treatment. After the forum, Oncology Frontier invited both experts to elaborate on their perspectives.
In-Depth Analysis丨Dr. Qiang Zhang & Dr. Li Wang: Neoadjuvant Immunotherapy Choices for Triple-Negative Breast Cancer

In-Depth Analysis丨Dr. Qiang Zhang & Dr. Li Wang: Neoadjuvant Immunotherapy Choices for Triple-Negative Breast Cancer

For neoadjuvant immunotherapy in triple-negative breast cancer (TNBC), do you prefer the "TP-AC" or "TP" regimen? At the 2024 Breast Cancer Summer Forum · Northern Salon's "Raising Questions and Seeking Answers" session, Dr. Qiang Zhang from Liaoning Cancer Hospital and Dr. Li Wang from Xingtai People's Hospital presented their viewpoints. Dr. Qiang Zhang favors the TP-AC regimen, while Dr. Li Wang opts for the TP regimen. After the session, Oncology Frontier invited both experts to elaborate on their perspectives.
2025 CASH丨Professor Ying Wang: Advances in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

2025 CASH丨Professor Ying Wang: Advances in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)

At the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH), Professor Ying Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a detailed summary of the latest research on CAR-T therapy for ALL. Her presentation covered the efficacy and safety of CAR-T therapies targeting various antigens, including CD19, CD22, and dual-target CAR-T approaches, as well as their application in specific patient populations. She also explored the factors influencing CAR-T therapy outcomes and discussed future directions to optimize this treatment for clinical use. Hematology Frontier has compiled the key insights from her presentation.
Gut Microbiota and Eating Disorders: A New Frontier in Neuroinflammation Research

Gut Microbiota and Eating Disorders: A New Frontier in Neuroinflammation Research

Could the gut microbiome be the missing link in understanding eating disorders? A groundbreaking study led by Dr. Sabrina J.P. Huwart, Dr. Nuria Morales-Puerto, and Dr. Amandine Everard (Université catholique de Louvain) sheds light on the interplay between gut microbiota, neuroinflammation, and food reward alterations—a critical factor in the development of eating disorders like anorexia nervosa, bulimia nervosa, and binge eating disorder.